Literature DB >> 22121096

MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.

Emma H Allott1, Joanne Lysaght, Mary Clare Cathcart, Claire L Donohoe, Robert Cummins, Sarah A McGarrigle, Elaine Kay, John V Reynolds, Graham P Pidgeon.   

Abstract

Overweight and obesity is linked to increased incidence and mortality of many cancer types. Of all cancers, oesophageal adenocarcinoma (OAC) displays one of the strongest epidemiological links with obesity, accounting for up to 40% of cases, but molecular pathways driving this association remain largely unknown. This study aimed to elucidate mechanisms underpinning the association of obesity and cancer, and to determine if visceral obesity is associated with aggressive tumour biology in OAC. Following co-culture with visceral adipose tissue explants, expression of genes involved in tumour cell invasion and metastasis (matrix metalloproteinase (MMP)2 and MMP9) were upregulated between 10-fold (MMP2) and 5000-fold (MMP9), and expression of tumour suppressor p53 was downregulated 2-fold in OAC cell lines. Western blotting confirmed these results at the protein level, while zymographic analysis detected increased activity of MMPs in OAC cell lines following co-culture with adipose tissue explants. When OAC cell lines were cultured with adipose tissue conditioned media (ACM) from visceral adipose tissue, increased proliferative, migratory and invasive capacity of tumour cells was observed. In OAC patient tumour biopsies, elevated gene expression of MMP9 was associated with visceral obesity, measured by visceral fat area, while increased gene expression of MMP9 and decreased gene expression of tumour suppressor p53 was associated with poor tumour differentiation. These novel data highlight an important role for visceral obesity in upregulation of pro-tumour pathways contributing to aggressive tumour biology, and may ultimately lead to development of stratified treatment for viscerally obese OAC patients.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22121096     DOI: 10.1002/mc.21840

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  14 in total

Review 1.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

2.  Trophoblast invasion and blood vessel remodeling are altered in a rat model of lifelong maternal obesity.

Authors:  Emily K Hayes; Daniel R Tessier; Michael E Percival; Alison C Holloway; Jim J Petrik; Andree Gruslin; Sandeep Raha
Journal:  Reprod Sci       Date:  2013-10-23       Impact factor: 3.060

3.  Golgi phosphoprotein 3 regulates metastasis of prostate cancer via matrix metalloproteinase 9.

Authors:  Wenzhi Li; Kai Qi; Zhanyu Wang; Meng Gu; Gang Chen; Fengfu Guo; Zhong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 4.  Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma.

Authors:  Leo Alexandre; Elizabeth Long; Ian Lp Beales
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

5.  Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro.

Authors:  Ricardo Ribeiro; Cátia Monteiro; Virgínia Cunha; Maria José Oliveira; Mariana Freitas; Avelino Fraga; Paulo Príncipe; Carlos Lobato; Francisco Lobo; António Morais; Vítor Silva; José Sanches-Magalhães; Jorge Oliveira; Francisco Pina; Anabela Mota-Pinto; Carlos Lopes; Rui Medeiros
Journal:  J Exp Clin Cancer Res       Date:  2012-04-02

6.  Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis.

Authors:  Emma H Allott; Melissa J Morine; Joanne Lysaght; Sarah A McGarrigle; Claire L Donohoe; John V Reynolds; Helen M Roche; Graham P Pidgeon
Journal:  Clin Transl Gastroenterol       Date:  2012-04-19       Impact factor: 4.488

7.  Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma.

Authors:  Niamh Lynam-Lennon; Ruth Connaughton; Eibhlin Carr; Ann-Marie Mongan; Naoimh J O'Farrell; Richard K Porter; Lorraine Brennan; Graham P Pidgeon; Joanne Lysaght; John V Reynolds; Jacintha O'Sullivan
Journal:  BMC Cancer       Date:  2014-12-03       Impact factor: 4.430

8.  Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction.

Authors:  Xiaofei Lu; Lingling Duan; Hongqin Xie; Xiaoxia Lu; Daolin Lu; Daopeng Lu; Nan Jiang; Yuxin Chen
Journal:  Onco Targets Ther       Date:  2016-07-18       Impact factor: 4.147

Review 9.  Esophageal Cancer Development: Crucial Clues Arising from the Extracellular Matrix.

Authors:  Antonio Palumbo; Nathalia Meireles Da Costa; Bruno Pontes; Felipe Leite de Oliveira; Matheus Lohan Codeço; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Cells       Date:  2020-02-17       Impact factor: 6.600

10.  Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma.

Authors:  Yongfeng Yu; Zhengping Ding; Hong Jian; Lan Shen; Lei Zhu; Shun Lu
Journal:  Cancer Med       Date:  2016-07-25       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.